Objective To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation in Asian patients with refractory glaucoma. Methods The study was a retrospective interventional case series conducted at a single institution between January 2004 and January 2006. The study population included 91 patients (91 eyes). Results A total of 70 patients were successfully treated (74.5%). Postoperatively, the median intraocular pressures declined significantly to 13 mm Hg (interquartile range: 10-20 mm Hg) on day 1 (Po0.001) and 17 mm Hg (interquartile range: 12-19 mm Hg) at the last follow-up examination (Po0.001). The cumulative probability of success according to KaplanMeier life-table analysis was 74% at 12 months and 43% at 2 years. Hazard of failure increased slightly with age, HR: 1.03 (95% confidence interval (CI) ¼ 1.00-1.05; P ¼ 0.044). The most common complication was hyphaemia at 12.77%. There were no serious complications involving loss of visual acuity or sight. Conclusions AGV implantation is an acceptable treatment for refractory glaucoma in high-risk patients with few additional options.

Vertically aligned ZnO/ZnTe core-shell nanowires were grown on a-plane sapphire substrate by using chemical vapor deposition with gold as catalyst for the growth of ZnO core and then followed by growing ZnTe shell using metal-organic chemical vapor deposition (MOCVD). Transmission electron microscope (TEM) and Raman scattering indicate that the core-shell nanostructures have good crystalline quality. Three-dimensional fluorescence images obtained by using laser scanning confocal microscope demonstrate that the nanowires have good optical properties. The core-shell nanowire was then fabricated into single nanowire field effect transistor by standard e-beam photolithography. Electrical measurements reveals that the p-type ZnO/ZnTe FET device has a turn on voltage of -1.65 V and the hole mobility is 13.3 cm2/V s.

No abstract

Achieving early detection at the onset of cancer is a major goal of cancer research. The early presence of aberrant DNA methylation makes the use of DNA methylation biomarkers an attractive candidate for early detection. Altered DNA methylation is ubiquitous in human cancers and specific methylation changes are often correlated with clinical features. DNA methylation biomarkers provide a range of opportunities for early detection, diagnosis, prognosis, therapeutic stratification and post-therapeutic monitoring. Furthermore, aging is one of the primary risk factors associated with cancer development. We conducted computational biology analyses of published High-grade serous ovarian cancer (HGSOC) epigenetic profiles using gene lists bearing human embryonic stem cell (hESC) characteristics. Through aging correlated features, epigenetic age-dependent marker panel on HGSOC was conducted. It is to be noted, the genes in the refined marker panel were found all included in the age-dependent features. The further experiment results showed not only the refined marker panel is able to represent the age-dependent features but performed better performance than the reported marker panel without associated with age parameter. Furthermore, the refined prognostic marker panel, including HOXA9, HSPA1A, and CALCA-associated with ovarian cancer and tumor growth, is strongly connected with literature support the potential for considering into clinical assay for patients' stratification and future personalized medicine interventions.